Acadia Pharmaceuticals (ACAD) Tax Provisions (2017 - 2026)

Acadia Pharmaceuticals' Tax Provisions history runs 10 years deep, the most recent figure standing at $300000.0 for Q1 2026.

• In Q1 2026, Tax Provisions fell 96.59% year-over-year to $300000.0; the TTM figure through Mar 2026 stood at -$260.6 million (down 824.56% YoY), while the FY2025 annual figure was -$252.1 million, down 897.17% from the prior year.
• Tax Provisions was $300000.0 for Q1 2026 at Acadia Pharmaceuticals, up from -$247.2 million in the prior quarter.
• In the past five years, Tax Provisions ranged from a high of $17.3 million in Q4 2024 to a low of -$247.2 million in Q4 2025.
• Historically, Tax Provisions has averaged -$12.2 million across 5 years, with a median of $831000.0 in 2022.
• The sharpest annual moves came in 2022 and 2025: Tax Provisions jumped 2209.52% in 2022, then sank 1527.21% in 2025.
• A 5-year view of Tax Provisions shows it stood at $831000.0 in 2022, then tumbled by 833.33% to -$6.1 million in 2023, then jumped by 384.28% to $17.3 million in 2024, then sank by 1527.21% to -$247.2 million in 2025, then jumped by 100.12% to $300000.0 in 2026.
• The last three Tax Provisions figures came in at $300000.0 (Q1 2026), -$247.2 million (Q4 2025), and -$27.2 million (Q3 2025), per Business Quant data.